Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 59-year-old Japanese woman with primary open-angle glaucoma underwent PreserFlo MicroShunt (PFM) (Santen Pharmaceutical Co., Ltd., Osaka, Japan) implantation in her left eye. Six weeks postoperatively, a conjunctival exposure of the posterior end of the device was observed, accompanied by aqueous leakage. The patient had no identifiable risk factors for exposure, such as previous conjunctival incisional surgeries, significant blepharitis, or needling procedures. Conjunctival advancement surgery was performed to cover the exposed device. After the sufficient dissection of scar tissue surrounding the PFM and the reapproximation of the conjunctiva, the device was successfully covered. Postoperatively, the filtration bleb remained formed, and the intraocular pressure (IOP) was controlled. No recurrence of device exposure was observed after 18 months of follow-up. Although PFM device exposure is a rare complication, it requires prompt surgical intervention to prevent infection and maintain IOP control. Conjunctival advancement surgery is an effective treatment option that allows for the repair of the exposure while preserving the filtration function of the device.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586878 | PMC |
| http://dx.doi.org/10.7759/cureus.72409 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical application prospects and challenges of preservative-free anti-glaucoma drugs].
Zhonghua Yan Ke Za Zhi
September 2025
Aier Glaucoma Institute, Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in Diagnosis and Application of New Materials, Changsha Aier Eye Hospital, Changsha 410015, China.
As the world's leading irreversible blinding eye disease, glaucoma is predominantly managed with pharmaceutical interventions in clinical practice. However, long-term use of traditional eye drops containing preservatives (e.g.
View Article and Find Full Text PDFAb-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma:5-Year Safety Results from a Randomized, Multicenter Study.
Ophthalmol Glaucoma
September 2025
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, England; Discipline of Clinical Ophthalmology and Eye Health, University of Sydney, Sydney, New South Wales, Australia.
Purpose: To compare the long-term safety of MicroShunt implantation with trabeculectomy in eyes with primary open-angle glaucoma (POAG).
Methods: This was a 3-year observational extension of a 2-year prospective randomized trial comparing clinical outcomes of MicroShunt implantation with trabeculectomy, both augmented with mitomycin C. Adverse events (AEs), intraocular pressure (IOP), and IOP-lowering medication use were recorded 36, 48, and 60 months after initial randomization.
Cemiplimab in advanced periocular conjunctival and cutaneous squamous cell carcinoma: a United Kingdom case series.
Orbit
September 2025
Adnexal, Moorfields Eye Hospital, London, UK.
Purpose: To evaluate the real-world efficacy, safety, and outcomes of cemiplimab for advanced periocular conjunctival and cutaneous squamous cell carcinoma (SCC).
Methods: Retrospective case series of adults treated with cemiplimab for periocular conjunctival or cutaneous SCC at Moorfields Eye Hospital (2021-2025).
Results: We included 9 patients (mean age 66, range 43-79; 56% female; 78% Caucasian).
Choroidal hemangioma in Sturge-Weber syndrome elucidated by ultra-widefield swept-source optical coherence tomography angiography.
BMC Ophthalmol
August 2025
Department of Ophthalmology, Peking University First Hospital, Beijing, China.
Background: Sturge-Weber syndrome (SWS) is a rare congenital phacomatosis disorder. choroidal hemangioma (CH) is one of the most common ocular manifestations. The advancements in swept-source optical coherence tomography angiography (SS-OCTA) provide us a comprehensive view of the CH.
View Article and Find Full Text PDFSurgical Management of Corneal Sequelae of Vernal Keratoconjunctivitis.
Semin Ophthalmol
August 2025
Department of Cornea and Anterior Segment Services, Shantilal Shanghvi Eye Institute, Mumbai, India.
Purpose: Vernal keratoconjunctivitis (VKC) is a chronic, recurrent, allergic ocular surface disorder affecting children and young adults, particularly in tropical climates. Corneal sequelae such as giant papillae (GP), shield ulcers, limbal stem cell deficiency (LSCD), and keratoconus (KC) often necessitate surgical intervention when medical therapy is inadequate. This review summarizes the current surgical strategies for managing VKC-related corneal complications and their outcomes.
View Article and Find Full Text PDF